Document registry — page 18
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low10 Mar 2026 -
In adults who have lost weight during treatment with an incretin receptor agonist, what happens to body weight after treatment is withdrawn?
Moderate09 Mar 2026 -
Research peptides with a declared GLP-1 specialty, SARMs and injectable oils. Factory-direct model.
09 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, is the effect of CJC-1295 maintained across the full duration of…
Low07 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over 52 weeks. The Institute holds no reported primary result for…
06 Mar 2026 -
Consultation on the draft monograph for Melanotan-II, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Mar 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High03 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over 68 weeks or longer. The Institute holds no reported…
03 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low03 Mar 2026 -
Randomised crossover, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low03 Mar 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
Moderate02 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
02 Mar 2026 -
Observational, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low02 Mar 2026 -
Consultation on the draft of this methodological review, which registers the question: What can be concluded from a development programme that was discontinued, and how…
01 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Mar 2026 -
Randomised crossover, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low01 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Exenatide maintained across the full duration of the contributing trials?
High27 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over 72 weeks. The Institute holds no reported primary result for this…
27 Feb 2026 -
Consultation on the draft of CEI-MS-11, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
26 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low26 Feb 2026 -
In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the apnoea–hypopnoea index?
Moderate25 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Peptides, SARMs, injectable oils and raw materials.
22 Feb 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Dulaglutide compared with the comparator…
High21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over 72 weeks. Primary result: The Institute holds a headline result indicating a…
Moderate21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Feb 2026 -
Single-arm open-label, phase 3 study of Orforglipron in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low21 Feb 2026 -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide). Ipamorelin activates the ghrelin receptor on pituitary somatotrophs, producing growth-hormone release through a pathway distinct from and…
Low20 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Feb 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…
Moderate19 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High18 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low17 Feb 2026 -
Consultation on the draft monograph for Epithalon, which the assessment committee released for public comment before ratification. The draft grades the compound's…
16 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the anchor…
Moderate15 Feb 2026 -
Custom peptide synthesis and amino acids. Founded 1998. ISO 9001 and cGMP certified, 1,500+ employees, 200+ patents.
15 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute…
Very low15 Feb 2026
page 18 of 41